BofA analyst Tazeen Ahmad raised the firm’s price target on 89bio to $24 from $17 and keeps a Buy rating on the shares. With additional cash infusion following an upsized secondary offering netting greater than $260M, by the firm’s estimates, and additional color on the ENLIVEN study following the investor call, BofA is more comfortable with 89Bio’s NASH program, it said in a research note on Friday.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ETNB:
- 89bio 16.92M share Secondary priced at $16.25
- 89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
- Morgan Stanley stays Overweight Akero Therapeutics after 89bio data in NASH
- 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 89bio announces $200M common stock offering
